Group 1 - The company Zhaoke Ophthalmology-B (06622) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] - Dongshenghua Pharmaceutical specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL™ PF [1] Group 2 - By June 2025, Tenpoint Therapeutics, Ltd., a partner of Zhaoke and developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]
兆科眼科-B(06622)拟与东生华制药于台湾地区共同推进BRIMOCHOL™PF的临床导论及未来商业化